Skip to content

Exogenous creatine kinase and platelet aggregation

Exogenous creatine kinase and platelet aggregation - Exogenous CK and platelets

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40674
Enrollment
6
Registered
2014-06-04
Start date
2014-06-12
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding platelet aggregation disorder

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Women between 18 and 50 years old, with no known disease or drug use.

Exclusion criteria

Exclusion criteria: Current disease, personal and family history of bleeding or coagulation abnormalities, intensive exercise in the three days prior to participation, drug use, use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) in the two weeks prior to participation, usage of the supplement creatine (or a creatine analogue), current smoking.

Design outcomes

Primary

MeasureTime frame
ADP induced platelet aggregation (area under curve and final aggregation) with different concentrations of creatine kinase added in vitro.

Secondary

MeasureTime frame
Endogenous plasma CK activity levels.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)